Statement by Chip Davis, President and CEO, GPhA Regarding the Trans-Pacific Partnership Agreement

PRESS RELEASE

WASHINGTON, DC (October 5, 2015) - “The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council strongly support efforts to improve worldwide patient access to affordable medicines. We are optimistic that the agreement announced today on the Trans-Pacific Partnership (TPP) brings us closer to achieving that goal by embracing competition from safe, effective biosimilar therapies."

Trade provisions that facilitate both the development of innovative, life-saving medicines and the availability of affordable generic medicines are a win for patients. We applaud the United States Trade Representative (USTR) and negotiating countries for working diligently in an effort to strike this balance.

GPhA and its members will continue to work with the USTR on the technical details of the final TPP to ensure that it promotes patient health and economic growth. The TPP presents an unprecedented opportunity to usher in a new era of global trade, patient access and health savings. We look forward to working with Congress and the Administration to make this historic agreement a reality.”